FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...